Valuation: Evaxion A/S

Market Cap 23.6M 20.98M 19.45M 17.69M 33.39M 2.24B 33.92M 234M 91.65M 1.17B 88.58M 86.7M 3.73B P/E 2026 *
-70.8x
P/E 2027 * -189x
Enterprise Value 23.6M 20.98M 19.45M 17.69M 33.39M 2.24B 33.92M 234M 91.65M 1.17B 88.58M 86.7M 3.73B EV / Sales 2026 *
-
EV / Sales 2027 * 5.05x
Free-Float
58.26%
Yield 2026 *
-
Yield 2027 * -
1 day+1.07%
1 week-7.82%
Current month-13.72%
1 month-12.11%
3 months-7.97%
6 months-36.40%
Current year-40.67%
1 week 2.72
Extreme 2.72
3.23
1 month 2.72
Extreme 2.72
3.35
Current year 2.72
Extreme 2.72
5.48
1 year 2.72
Extreme 2.72
8.1
3 years 1.2
Extreme 1.2
68.05
5 years 1.2
Extreme 1.2
1,252
10 years 1.2
Extreme 1.2
1,252
Manager TitleAgeSince
Chief Executive Officer 59 24/11/2025
Corporate Officer/Principal 49 11/08/2008
Director of Finance/CFO 53 01/11/2024
Director TitleAgeSince
Chairman 58 25/11/2020
Director/Board Member 56 01/01/2018
Director/Board Member 68 25/05/2021
Date Insider Type Main position Quantity % Market Cap. Importance
16/4/26 Other

Director

2,376 0.0006%
18/3/26 Other

Chief Financial Officer

645,750 0.1549%
18/3/26 OtherCompany 360,406 0.0864%
Change 5-day change 1-year change 3-year change Capi.($)
+1.07%-7.82%-58.32%-93.42% 23.6M
-6.60%-8.56%+49.38%+63.51% 65B
+0.03%+5.56%+9.10%+69.05% 51.2B
-4.09%-0.11%+2.22%+53.15% 51.19B
-1.53%+2.70%+30.48%+34.12% 43.93B
-1.34%+4.12%+16.64%+115.13% 41.96B
-5.97%-6.22%+228.95%+454.22% 38.14B
+6.53%+8.02%+16.40%+53.41% 33.24B
-0.90%-10.49%+37.09%-3.70% 25.2B
-1.07%+2.33%+19.43%+9.98% 22.5B
Average -1.39%-1.07%+35.14%+75.54% 37.24B
Weighted average by Cap. -2.20%-0.47%+44.24%+96.52%

Financials

2026 *2027 *
Net sales - 4.67M 4.15M 3.85M 3.5M 6.61M 443M 6.71M 46.25M 18.13M 231M 17.53M 17.15M 737M
Net income -15.56M -13.83M -12.82M -11.66M -22.01M -1.48B -22.36M -154M -60.42M -771M -58.4M -57.16M -2.46B -11.81M -10.5M -9.73M -8.86M -16.71M -1.12B -16.98M -117M -45.87M -585M -44.33M -43.39M -1.87B
Net Debt - -
Projected Income Statement - Annual - Evaxion A/S
Logo Evaxion A/S
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Employees
46
Date Price Change Volume
16/10/26 USD 2.830 +1.07% 78,129
15/10/26 USD 2.800 0.00% 35,108
14/10/26 USD 2.800 +1.45% 50,396
13/10/26 USD 2.760 -8.00% 134,062
12/10/26 USD 3.000 -2.28% 60,824
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Evaxion A/S
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.830USD
Average target price
11.25USD
Spread / Average Target
+297.53%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evaxion A/S
  1. Stock Market
  2. Stocks
  3. EVAX Stock